Alzheimer’s Disease Atlas: Mapping global preparedness for dementia

The Alzheimer’s Disease Atlas is the first of its kind platform highlighting how countries diagnose, treat and support people living with dementia.

The platform brings together the key indicators needed to assess a country’s preparedness for Alzheimer’s disease and related dementias, helping advocates, policymakers and healthcare leaders identify where people are being left behind.

Providing a country-by-country insight into dementia policies, diagnosis, treatment and care, research and support available the AD Atlas exposes stark inequalities around the world. Demonstrating that people living with dementia can face very different experiences of diagnosis, care and support depending on where they live.

Despite over 55 million people living with dementia globally and significant advances in treatment, governments and healthcare systems are failing to keep pace. While the burden of Alzheimer’s disease and related dementias continues to increase, only 24.2 percent of countries that adopted the WHO Global Action Plan on Dementia have a fully funded national dementia plan.

The AD Atlas reveals, not only the scale of the global disparity, but the systemic gaps that continue to fail people living with dementia and their families.

The webinar will highlight key findings and show how comparative country data can inform policy dialogue, prioritisation, and resource allocation.

We are pleased to offer AI translation for this webinar in over 60 languages, including: Arabic, Bengali, Cantonese, Chinese (Simplified), Chinese (Traditional), Croatian, Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Greek, Gujarati, Hebrew, Hindi, Indonesian (Bahasa), Italian, Japanese, Korean, Malay, Persian, Polish, Portuguese, Serbian, Slovak, Spanish, Swahili, Swedish, Tagalog, Tamil, Thai, Turkish, Urdu, Vietnamese.

The webinar will be available for viewing on ADI’s YouTube channel after the event.

Date & Time

You can choose to attend one or more of the following webinars (times shown are London time):

• Thursday 22 October 2026, 10:00 AM
• Thursday 22 October 2026, 4:00 PM

Speakers

Dr Stéphane Epelbaum – International Therapy Area Lead Medical Affairs Neurology and Pain, Eli Lilly

Stéphane Epelbaum, MD, PhD is a neurologist who took part in helping shift the concept of Alzheimer’s disease from that of an unspecific dementia to a precise clinico-biological entity. Stéphane has been at the forefront of the clinical AD research field for the last 20 years and part of the international working group on AD until 2021.

He participated in more than 30 clinical trials and was also part of a data science lab in which he contributed to neurodegenerative diseases digital modelling.

Since November 2021, Stéphane has lead the medical affairs team in Eli Lilly international neuroscience working to bridge the gap between clinical development of medical innovation and their implementation in clinical practice.

Laura Castro-Aldrete – Research Partnerships Lead, Alzheimer’s Disease International

Laura Castro-Aldrete, PhD, is ADI’s Research Partnerships Lead, working to advance research initiatives and disseminate findings. She coordinates partnerships with academic institutions and project partners, and works with ADI’s Medical and Scientific Advisory Panel and Global Dementia Expert Panel.

Previously, Laura led mental and brain health projects in the non-profit sector. She has lived in Mexico, Italy, Sweden and the UK. She holds an MSc in Biotechnology and Enterprise and a PhD in Neuroscience from the University of Manchester, and has worked as a postdoctoral researcher at the Karolinska Institute and an invited lecturer at Tec de Monterrey. Her grandmother’s diagnosis inspired her dedication to dementia care.

Patricia Saletti – Research Partnerships Coordinator, Alzheimer’s Disease International

Patricia G Saletti, PhD, supports ADI’s research partnerships and collaborates on the coordination of research initiatives and projects. She has a background in neuroscience and extensive experience in programme and portfolio management within the non-profit healthcare sector.

She previously worked on strategic investments and managed research funding at the Alzheimer’s Drug Discovery Foundation (ADDF). After completing her studies in Brazil, she moved to New York to conduct postdoctoral research on neurodegeneration at the Albert Einstein College of Medicine.

Chris Lynch – Deputy CEO and Director of Policy, Research, Communications and Publications, Alzheimer’s Disease International

Chris is an international leader in healthcare policy, advocacy, research and communications, with over 30 years’ experience. He has spent the past 14 years in the dementia sector, working at the forefront of global efforts to strengthen policy and health system responses. His work spans national dementia plans, international advocacy, research and awareness.

As Director of Policy, Research, Communications & Publications, Chris leads ADI’s engagement with global bodies including the WHO, UN, G7 and G20, and oversees policy, research and flagship initiatives such as World Alzheimer’s Month and the World Alzheimer Report. He is a member of the WHO Civil Society Working Group for Non-Communicable Diseases.